ENCO Pharmaceutical Development Adds ICP-MS cGMP Services
JACKSONVILLE, Fla, April 10, 2018 /PRNewswire-iReach/ -- ENCO Pharmaceutical Development, Inc. (EPDI) announces the addition of ICP-MS cGMP services to support Elemental Impurities testing, USP <232> and USP <233>.
The addition of this new resource further strengthens EPDI's analytical capabilities and will be used to not only support the recent official changes to the USP but also to provide assistance for a variety of other product development needs.
"We are pleased to offer our customers this new service", said Mr. Richard Camp, President of ENCO Pharmaceutical Development, Inc. "With decades of experience in elemental analysis, we welcome the recent inclusion of the ICH Q3D Elemental Impurities guidance into the USP, and look forward to working with our customers to address the new requirements."
EPDI continues to expand its facilities and capabilities to accommodate the growing needs of the pharmaceutical, animal health care and medical device industries.
About the Company:
ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC. The company works with a variety of organizations in both the pharmaceutical, animal health and medical device industries, including global, mid-size and small firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit http://www.encopharma.com.
Media Contact: Keith Hurley, ENCO Pharmaceutical Development, In c., 3365413270, [email protected]
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE ENCO Pharmaceutical Development, Inc.
iReach LastName, iReachCompany, 111-222-3333, [email protected]
Share this article